Clinical Trials Browser

Interventional × Azacitidine × Gastrointestinal × Clear all

Pancreatic Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

10 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Phase 1 Terminated

272 enrolled

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Phase 1/2 Completed

93 enrolled 24 charts

CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT01845805 2022-10-04

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Phase 2 Completed

49 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02811497 2021-04-01

METADUR

Phase 2 Completed

28 enrolled

BreastGastrointestinalGynecologic

Microsatellite Stable Colorectal Carcinoma

NCT01193517 2020-04-15

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Phase 1/2 Completed

26 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1 Completed

169 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT02260440 2019-09-17

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Phase 2 Completed

31 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT01386346 2018-12-12

VEOX

Phase 1 Completed

12 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT01105377 2014-08-01

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

47 enrolled 6 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01167816 2014-05-20

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Phase 1 Terminated

9 enrolled

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

Azacitidine and Pembrolizumab in Pancreatic Cancer

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

METADUR

Azacitidine and CAPOX in Metastatic Colorectal Cancer

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

VEOX

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer